Loading…

JEOL Ltd.6951.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of electron microscopes and other scientific/analytical instruments for research and industry.

≈ Japan's Thermo Fisher for electron microscopesMomentum weak 22
Mkt cap
$2.12B
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$15.7M
20-day average traded
Fwd P/E
15.5×
forward earnings
ROIC−WACC
-1.9 pp
WACC 12.9%
Hurdle
+12 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥6,802
1D+2.4%
1W-0.3%
1M-9.7%
3M-23.1%
6M-2.2%
YTD+35.2%
1Y+30.0%
ATR %5.6%
52w lowhigh26.5% off high

What JEOL does

Japanese maker of electron microscopes and other scientific/analytical instruments for research and industry.

Sells large, high-priced instruments to labs, with service and parts after the sale, so installed machines keep generating income. Government and university budgets and chipmakers' R&D spending drive orders. It also makes electron-beam writers used to draw chip patterns in semiconductor manufacturing.

In one line: Japan's Thermo Fisher for electron microscopes.

Products and services

  • Electron microscopes
  • Mass spectrometers/NMR
  • Medical devices (MRI, clinical)
  • Industrial equipment

Customers

  • Universities/research labs
  • Semiconductor/materials companies
  • Hospitals

Where it sits in the supply chain

  • Health care/Industrials
  • Scientific instruments
  • Electron microscopes, mass…

What could go right

  • Semiconductor R&D/metrology spend
  • Academic research funding

What could go wrong

  • Research budget cyclicality

Moat: narrow (process know-how, installed base, brand). Deep imaging/spectroscopy know-how and installed base among researchers worldwide.

Headquarters: Tokyo, Japan · Founded: 1949 · Employees: 3,731

Named competitors

JEOL at a glance

Size JEOL (6951.T) is a Japan Health Care company (Medical Specialties) with a market value of $2.12B, the 472nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥6,802 on 18 Nov 2026.

Performance Over six months the shares fell 2.2%, against +3.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue fell 14.8% over the last twelve months (peer median +7.9%); the operating margin is 11.8% (peer median 15.2%).

Valuation It trades at 15.5× forward earnings against a peer median of 24.1× (5th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.9 points below its cost of capital (12.9% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 20266951.T 105Peer median 101
Six months, rebased to 100: JEOL against the median of its 20 peers (local-currency closes).

JEOL financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥163B¥179B¥197B¥174B¥163B
Revenue growth—-9%+13%+7%—
Gross profit¥76.8B¥81.1B¥90.6B¥77.5B¥71.0B
EBITDA¥25.2B¥31.5B¥40.8B¥32.3B¥29.1B
Net income¥15.5B¥22.1B¥18.7B¥21.7B¥17.8B
Free cash flown/a¥2.51B¥20.1B¥12.1B-¥2.68B
Capital expendituren/a¥15.1B¥4.26B¥3.48B¥6.39B
Total debt¥9.39B¥27.1B¥9.28B¥15.8B¥12.5B

Quarterly statements and history in the cockpit →

JEOL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-25%0%+25%ESTADRW8VCYTBONEXMETN2276688029EKTA-B300529MEDNEOG002901SKAN268A69601066MOVEEBOPOLYMED6951.T6-month return →1-month return →
Up and to the right = strong over both horizons. JEOL is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×50×100×150×DRW8VCYTBONEXMETN2276688029EKTA-B300529MEDNEOG002901SKAN69601066EBOPOLYMED6951.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JEOL is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%DRW8VCYTBONEX2276688029EKTA-B300529002901SKAN268A69601066EBO6951.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. JEOL is the large dot.

JEOL competitors and peer comparison

Head to head with its named competitors (6951.T vs TMO vs BRKR vs 268A.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
JEOL 6951.T$2.12B-2%-15%12%15.5×22.2%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Bruker BRKR$9.66B+43%+2%10%27.0×25.4%
Rigaku 268A.T$1.85B-54%+9%16%23.1×18.3%

How JEOL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JEOL against its 20 peers (data as of 18 Nov 2026)
Measure6951.TPeer medianRank in peer set
1-month return-9.7%-0.6%4th lowest of 21
6-month return-2.2%+3.1%7th lowest of 20
Distance from 52-week high-26.5%-18.1%8th lowest of 21
Revenue growth (TTM)-14.8%+7.9%lowest of 21
Operating margin11.8%15.2%9th lowest of 21
Forward P/E15.5×24.1×5th cheapest of 19
Growth the price implies (Req g, 7 yrs)22.2%7.6%most demanding of 14
Growth delivered (Del g)+10.2%+10.4%7th lowest of 14
Hurdle (Req g minus delivered)+12.0 pp-2.8 ppmost demanding of 14
ROIC minus cost of capital-1.9 pp+0.6 pp7th lowest of 21
EV / EBITDA12.4×17.1×4th cheapest of 15
Net debt / EBITDA-1.0×-0.1×6th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a

Questions

Who are JEOL's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Bruker (BRKR), Rigaku Holdings (268A.T). The cockpit's measured peer set (industry) also includes Establishment Labs (ESTA), Draegerwerk AG & Co. KGaA (DRW8.DE), Veracyte (VCYT), Bonesupport (BONEX.ST), Metall Zug (METN.SW), Shanghai Conant Optical (2276.HK).
Is JEOL expensive compared with its peers?
On forward p/e it trades at 15.5× against a peer median of 24.1×, 5th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has JEOL stock performed?
Over six months to 18 Nov 2026 the shares returned -2.2% against +3.1% for the median peer; over one year +30.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.